univers coverag
calendar event
medic meet aid societi societi neurointervent surgeri
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
digit front mco vs
bottom line digit health inflect point race toward own front door
american consum manag care organ particular
op ralli front runner technolog player chomp bit get piec
action continu believ mco chang agent space given
sit patient/provid fulcrum best place offer seamless consum digit
experi integr network benefit design recent announc op
american well/samsung partnership link aapl entri electron health record ehr
link integr smartphon app offer color face healthcar engag
american consum chang come year partnership telehealth player
prefer even sole sourc clearli posit catalyst acceler adopt
bode well nr american mdlive
race toward own digit front healthcar continu escal pace unh
ralli antm announc telehealth partnership samsung american
antm announc telehealth partnership samsung android smart phone platform
american anoth data point underscor race ownership digit front
aapl recent move ehr point aspir leverag industri lead market share smart
phone digit front healthcar consum
separ see mco/telehealth partnership pois acceler adopt bode well
american mdlive dr demand myriad telehealth compani sprung
mco retail player ink prefer telehealth network sometim even sole sourc
though relationship appear exclus
meaning could gener restasi teva
bottom line juli bridg goal date op gx version restasi
cyclosporin ophthalm emuls dri eye soon approach could soon see first
gener approv start come restasi us sale
multipl gener approv includ teva coverag univers expect
first wave believ littl expect meaning
contributor either two compani consensu attribut signific valu
gx restasi even slightli conserv
estim teva said believ guarante
crowd market onset given high bar set fda approv
gener therefor believ teva risk/reward skew
posit ahead potenti impend first gx restasi approv
estim upsid mylan/teva either gener restasi
market blue sky scenario
best visibl applic statu although note sever filer
also like close approv
legal side still await pend appeal court decis assum launch
bottom line restructur announc achaogen enabl manag focu effort
key prioriti zemdri commerci launch drive effici use capit
news come soon zemdri launch understand manag decis
work time commerci medic affair team roughli
personnel respect remain un-impact restructur continu focu
launch see prudent decis board manag team
believ would view increment posit investor focu come
week month zemdri launch trajectori remain key driver
stock near term continu remain construct sale lp vs
consensu reiter outperform rate
compani current presid cfo cso would step september/ octob
conjunct manag chang achaogen wise focus resourc
advanc develop program repres biggest commerci opportun
compani expect run rate oper expens sg remain
view chang alter valu proposit compani
bottom line reiter guidanc announc jason boucher replac jonathan
wilcox cfo leav new opportun leav septemb mr
boucher current vice-president financ chief account offic treasur assum cfo
role octob also reiter ebitda less nci guidanc mm vs estim
consensu guidanc lower mm juli reflect op
settlement bring member network
jason boucher replac jonathan wilcox cfo leav new opportun leav
septemb
pleas see link note settlement lower guidanc link
pleas see link preview link
solid result net one-tim mg gather momentum pt
 methodolog averag dcf price-to-earnings
bottom line alexion report financi result consensu revenu
ep compani disclos soliri myasthenia gravi gmg
launch exceed expect alreadi contribut quarter estim
quarter support one-tim benefit us demand pull
ex-u tender order revenu still would exceed consensu without
benefit alexion oper margin reach quarter record sinc
demonstr impact compani restructur effort manag increas
element guidanc coupl gmg trajectori anticip materi upward
revis consensu estim come week financi perform
benefit stock key upcom catalyst achiev soliri neuromyel
optica nmo phase trial year-end launch likewis manag
life-cycl expans strategi consist improv iv formul multipl
subcutan dose formul appear sensibl us increas expect
revenu durabl compani foundat franchis increas revenu
estim ep estim consensu
higher longer term new price target reiter
outperform rate alexion stock
revenu mm ep exclud option expens
stabl enough portfolio challeng mount mp pt
 methodolog averag dcf price-to-earnings p/sale
bottom line yesterday kept streak strong result large-cap biotech
compani beat consensu estim revenu earn also
exceed above-consensu forecast despit price pressur domest intern
market still manag keep total revenu grow total revenu
consensu estim one-tim
item contribut approxim result oper revenu grew
adjust item like larg cap compani pledg vow abstin
price increas price contribut year year top line perform oper
margin expect share repurchas quarter contribut
posit pro forma earn growth beat consensu estim
despit perform medium long term growth outlook compani
uncertain given immin challeng biosimilar launch neulasta epogen
eros aranesp increas competit challeng enbrel unclear us
whether launch aimovig support gener free good program launch
continu growth xgeva prolia hand nich product off-set eros
compar peer pharma biotech compani late stage pipelin remain rel lean
departur two senior commerci execut reassur investor
compani near term outlook base quarter result manag comment
make modest chang revenu forecast year increas
ep estim year base lower share count chang chang peer
compani multipl increas price target reiter market perform
rate stock
revenu million dilut non-gaap ep
new product cycl drive continu growth acceler
pt deriv rang dcf valuat deriv base case upsid scenario
supplement ev/fcf ev/ebitda analys
bottom line share trade today despit deliv believ solid
quarter compani demonstr acceler oper sale --
 intern come top end guidanc rang y/i
ad full point sequenti sale growth continu oper leverag margin
improv bp vs vs ep guidanc rais
repres penni increas impli back half guidanc admittedli
print bit complic bax recent slew consist beat rais quarter given
unexpect weak nutrit medic deliveri due seemingli transit issu
bring suppli on-board mexico customers/distribut partner continu ramp post-
hurrican maria cap potenti sale upsid otherwis would seen view
weak share buy opportun reiter top large-cap pick
still see upsid potenti reiter top-lin guidanc oper driven
new product cycl across busi includ continu roll-out amia periton
dialysi cycler japan launch kaguya pd periton dialysi renal recent
approv infus system spectrum iq canada evo iq europ
europ launch tisseel prima advanc surgeri regardless continu believ
drive sustain consist out-performance forese futur potenti upsid
recent updat long-term sale guidanc compound-annual-growth-rate time-frame
believ still underappreci street signific financi flexibl
balanc sheet like increasingli activ share repurchas
ep estim move higher
revenu mm ep includ stock compens expens
solid result give relief pipelin need deliv
 methodolog averag method dcf price earn price sale
bottom line yesterday morn celgen deliv solid revenu earn beat
financi result rais revenu earn respect far
tell posit result larg due organ growth benefit modestli
posit price one time item reassuringli compani timelin key pipelin program
remain track even re-evalu plan studi otezla ulcer coliti reflect
posit develop decis make highlight initi take-away note note strong
fundament perform revlimid pomalyst us drove top-line beat
substanti absorb higher oper expens follow juno acquisit celgen aggress
share repurchas activ quarter result ep beat
manag declin comment on-going revlimid settlement discuss dr reddi
continu cloud sentiment stock
quarter result updat model reflect recent oper perform
revenu million ep exclud option expens
bottom line report revenu ebitda ep beat driven price better-than-
expect volum opex effici rais revenu ebitda guidanc due
time close divestitur ep cffo guidanc lower due increas interest expens
recent debt refinanc remov near-term default risk would appear pressur
account receiv despit lower yoy capital-expenditure divestitur price solid invest
higher acuiti servic line also reflect surgeri volum adjust admiss improv
invest ambulatori site servic suppli swb improv opex beat
debt restructur remov near-term default risk expens increas interest weaker cash
flow expect tomorrow call edt focu fundament trend cash flow guidanc
divestitur program de-lever
revenu ebitda ep beat driven price better-than-expect volum improv
revenu ebitda guidanc rais delay time close divestitur
cffo guidanc lower mm due interest rate headwind sever payment
collect ar despit lower capital-expenditure divestitur
ss revenu see improv underli hospit portfolio
price solid servic line invest shift lower acuiti ob lower cost site
servic also reflect hospit surgeri volum trend
adjust admiss beat consensu build ambulatori site servic though volum guidanc
lower
oper expens manag also improv swb opex beat
remain highli lever net debt ebitda estim leverag remain
throughout focu de-lever
manag host confer call discuss result juli et dial-in detail
thv sale fall slightli expect acceler
ep
bottom line ew share like trade friday reaction anoth quarter somewhat
disappoint thv transcathet heart valv sale miss pretti modest --
consensu -- expect share come pressur given ew momentum stock
stock came pressur today due lacklust fb result anyth short clean beat
rais could see continu pressur friday repres second consecut
quarter underli global thv sale growth first string two consecut quarter
growth sinc could shake investor confid compani abil acceler
growth back half year hit guidanc high end rang global
thv sale ew cite competit share loss ex-u driver below-market growth
second quarter row still point ew driver thv sale growth
acceler come line includ european launch centera sapien
ultra premium-pr product think ew thv
sale guidanc -- also ep guidanc -- absolut achiev given
also think slower steadier intermedi risk ramp play -- like
true low risk approv come line late -- also think tough
ew drive consist beat rais go forward share still trade price-to-earnings
ep wonder sustain multipl even low risk data catalyst
march posit outcom seemingli alreadi larg price
sale outlook unchang ep estim move higher
revenu mm non-gaap dilut adjust ep
 methodolog ev/ebitda ebitda
bottom line rais pt essenti maintain
estim view guidanc return ss behavior revenu growth achiev
continu ramp demand strong price easier comp absent hurrican
regulatori headwind ex health plan bh revenu price track
compani expect shift patient residenti acut behavior treatment
patient day volum slightli expect acut price trend solid increas
acuiti line op report yesterday volum slightli expect
difficult comp past year balanc sheet remain solid leverag like
regulatori settlement bh would posit catalyst pt move
contempl ev/ebitda estim
slight revenu miss solid price offset weaker volum ebitda miss driven opex
chang guidanc
return ss behavior revenu appear achiev easier comp strong price improv
volum pent demand effort address staf issu captur volum
acut volum weak off-set stronger price growth line shift observ
capital-expenditure focus bh jv acut hospit ad ambulatori site bed add ac
balanc sheet strongest coverag
regulatori settlement appear like posit catalyst
rais pt
revenu mm bad debt ep ex one-tim item
earn deal backlog still flat sequenti
bottom line vocera report good result deal flow quarter robust
sever larg win total backlog defer revenu flat sequenti basi
indic backlog trend normal ramp activ expect
enabl deliv revenu expect howev worri lack
backlog growth saw continu success sell larger deal quarter book
four contract worth least includ win walter reed manag describ
larg deal pipelin sizabl growth opportun market highlight
call good potenti middl east australia uk cite continu
demonstr strong oper leverag report robust gm om expans slightli
lower estim pt stand like deliv result
deal-flow four client seem unusu us backlog defer
revenu remain flat sequenti basi maintain mp
continu growth larg deal pipelin support dedic strateg sale team
continu device/softwar mix shift may worth watch
market remain strong area growth
adj ep guidanc reduc revenu guidanc re-affirmed guid expect
tweak estim pt stand
non-gaap ep ep exclud non-cash interest merger cost stock comp amort
overdon bullish stemi commentari hint growth
ev/sal multipl estim
bottom line share trade meaning morn despit otherwis
solid beat rais quarter guidanc move even higher midpoint
beat impli street number year like move higher due better-than-
previous expect perform move year think key issu may pressur
share today macro move driven faang lacklust fb nr result drive
under-perform momentum med-tech name call commentari around stack
impella revenu deceler quarter quarter acceler
direct guidanc sale sequenti
lower acknowledg -- even share today --
expens would still buyer weak would expect stock recov
come week day convinc year stack revenu perfect
indic go-forward growth trajectori look high-growth compani
 ew mp op op op quarter
year stack revenu growth deceler follow sale growth acceler
follow quarter even without specif catalyst relat sequenti
direct guid believ manag like conserv especi given fact
tct -- largest us-bas intervent cardiolog meet -- fall septemb
year vs last year bullish commentari call paper
editori publish jacc journal american colleg cardiolog hint likelihood
impella success stemi -- indic would repres next leg growth
doubl
revenu mm dilut gaap ep
ep
bottom line reiter strong convict pt offer attract
upsid solid modest beat driven though off-set miss tax rate
much lesser extent sg ratio prevent bigger headlin ep beat margin expand well
commerci govern segment ceo gail boudreaux high qualiti manag
team includ pete haytaian commerci felicia norwood gov john gallina cfo
recent prakash patel dbg report continu extract valu state
cross shield brand lead local market share asset go forward expect proof point
membership growth across segment manag across commerci risk individu medicar
group retire medicaid flat expand margin specialti penetr continu
captur greater share wallet ingeniorx expect gener annual cost save
least bottom line phase run-rat basi
fuel share gain margin segment diversifi busi group across key pillar
aim specialti caremor new digit health function smart phone pois
drive cost structur improv unlock valu payor agnost platform see
greater visibl financi pt contempl acceler growth margin expans
diversif revenu stream repres pe ep
adjust ep number may add total due round
headwind persist global price pressur continu pt
 methodolog ep
bottom line follow earn report call increment cautiou
pharma distribut group stock continu commentari stabil
gener good distribut group us pharma op miss estim
analysi price data show meaning improv link brand price
sound favor us manag describ brand price rate less
would normal expect juli continu headwind uk franc canada
also like persist guidanc re-affirmed segment
guid lower-end prior rang earn actual declin
y/i basi surpris medic divis oper incom grow y/i
basi reduc forward estim pt reiter mp
adjust ep exclud acquisit relat cost acquisit relat amort non-recur item
includ awp reserv lifo adjust
post-op pain dinner discuss continu posit ahead
caus confus alzheim amyloid still black
averag dcf price-to-earnings p/sale
minor contamin heart clinic hold studi
continu provid incent shift lower site
propos rule potenti posit exparel
solid growth momentum increas pt
 methodolog ep growth impli price-to-earnings
ep cash
 methodolog averag dcf price-to-earnings p/sale
cash ep
stori
ep
set keep florida medicaid win
full circl back domin hiv busi founder exit left mp pt
 methodolog averag price-to-earnings large-cap revenu multipl slower-growth
medic co sum part exist franchis dcf
 methodolog ev/ebitda ebitda
ep
impress quarter set stage higher growth profil ahead pt
strong symdeko launch boost top line tax effect ep come pt
 methodolog average ep rev disc dcf
wacc tg
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
note ph criteria differ nccn guidelin meant trial
result directli compar prior studi
discuss fda on-going primari endpoint determin
told endpoint may similar select ph design
link note
recent pamrevlumab result suggest convent ct scan may accur predict
resect lapc patient
success pamrevlumab neoadjuv set may depend chang resctabl
standard adopt clinic regulatori commerci endpoint
aug omadacyclin antibiot skin pneumonia adcom
key catalyst remain time-frame conven adcom aug
potenti approv oct time-frame could move stock meaning
view fda decis panel indic concern
link view panel public forum review posit risk/
benefit profil omadacyclin evidenc last nce antibiot pneumonia
sinc adcom conven
continu view data packag omadacyclin support approv
believ current level street underappreci valu omadacyclin
gain clariti key discuss topic brief document
releas publicli two busi day ahead adcom date
pdufa date expect octob
mid-august hire extern sale rep cologuard screen
cologuard highli under-penetr strong popul need
colorect cancer screen believ could deliv penetr
revenu longer term penetr ttm sale
recent analysi util leerink healthcar advanc analyt suggest
hire extern rep remain track complet mid-august earlier
timelin highlight
view revenu growth depend fast compani hire sale rep
particularli extern rep harder find hire intern one
turn drive new physician reorder catalyz growth exist physician order
rep hire faster abl reach new pcp aggress
abl serv exist account sooner and/or frequent -- ultim drive upsid
estim take month rep becom fulli product
result updat like late juli
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
sourc leerink research compani inform factset price prior day
fda adcom joint meet drug safeti risk manag anesthet
fda adcom antimicrobi drug omadacyclin acut bacteri skin skin
structur infect absssi community-acquir bacteri pneumonia cabp
medcac panel t-cell therapi
fda public hear biosimilar silver spring md
pdufa teva fremanezumab cgrp migrain
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa xyrem cataplexi excess daytim sleepi
pdufa revefanacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
societi neurointervent surgeri
american associ physicist medicin
american associ clinic chemistri
world congress cancer skin
european societi cardiolog esc
associ offici analyt chemist aoac
societi laparoendoscop surgeon minim invas surgeri week
intern network fatti acid oxid research manag
world congress pharmaci pharmaceut scienc fip
societi studi inborn metabol diseas ssiem symposium
bioprocess intern confer exhibit
advanc genom biolog technolog agbt precis meet
societi minim invas spine surgeri smiss annual forum
american societi hypertens joint w/ american heart associ aha
european migran headach trust intern congress ehmtic
american academi otolaryngolog head neck surgeri aao-hnsf
intern societi research iser biennial meet
intern associ studi pain iasp world congress pain
european academi dermatolog venereolog eadv
american societi surgeri hand assh
advanc genom biolog technolog agbt precis meet
associ vascular access annual scientif meet
heart failur societi america hfsa annual scientif meet
deadlin lpnt solicit altern acquisit propos
go live az
model celg ew
recent updat pleas contact leerink repres wish
review
biopharma preview gener pain women anti-infect
hcit distribut preview pocket opportun
medic suppli devic individu co preview cardio large-cap
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
note wild ride ahead aaic data could drive
 ctad medacorp call aducanumab abeta hypothesi
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
hcit distribut -- flash minut stori appear one-sid
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
deal capac
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
biopharma atop derm still without ped leerink dupi derm survey
 hiv survey rapid adopt biktarvi challeng outlook
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
medic devic survey direct posit mute hope
teva rais austedo sale analysi posit medacorp physician survey
 open ablat atriclip drive near term growth mi longer term
 differenti poc signific runway impli upsid pt
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
